<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Toward Valid Generative Clinical Trial Data with Survival Endpoints - Health AI Hub</title>
    <meta name="description" content="This paper introduces a novel Variational Autoencoder (VAE) designed to generate synthetic clinical trial data, specifically addressing the complex task of mode">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Toward Valid Generative Clinical Trial Data with Survival Endpoints</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.16551v1" target="_blank">2511.16551v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-20
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Perrine Chassat, Van Tuan Nguyen, Lucas Ducrot, Emilie Lanoy, Agathe Guilloux
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG, stat.AP, stat.ME, stat.ML
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.95 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.16551v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2511.16551v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces a novel Variational Autoencoder (VAE) designed to generate synthetic clinical trial data, specifically addressing the complex task of modeling time-to-event survival outcomes alongside mixed-type covariates. The VAE operates within a unified latent variable framework and uniquely does not assume independent censoring, outperforming existing GAN-based approaches on fidelity, utility, and privacy, while identifying and partially mitigating critical miscalibration issues in type I error and power.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research is highly relevant to medicine and public health by offering a potential solution to accelerate drug development, reduce costs, and enhance the feasibility of clinical trials, particularly in challenging areas like oncology and rare diseases where patient recruitment and data sharing are often bottlenecks. It directly impacts the design and validity of future clinical research.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The AI application involves using generative models (specifically VAEs) to create synthetic control arms and synthetic patient data for clinical trials. This addresses issues such as patient recruitment, cost reduction, ethical data sharing while preserving privacy, and mitigating imbalances in treated vs. control groups, especially for complex time-to-event outcomes in areas like oncology and rare disease research.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Addresses critical challenges in clinical trials, including slow enrollment, high costs, and fragmented patient populations, by proposing synthetic control arms (SCA) generated via AI.</li>
                    
                    <li>Introduces a novel Variational Autoencoder (VAE) specifically designed for jointly generating mixed-type covariates and complex time-to-event (survival) outcomes, which are primary endpoints in oncology and rare disease trials.</li>
                    
                    <li>The proposed VAE operates within a unified latent variable framework and, crucially, does not rely on strong assumptions like independent censoring, a common limitation of prior GAN-based methods.</li>
                    
                    <li>Evaluated the model in two practical scenarios: (i) data sharing under privacy constraints, where synthetic controls replace original sensitive data, and (ii) control-arm augmentation to address imbalances between treatment and control groups.</li>
                    
                    <li>The VAE consistently outperformed conventional GAN baselines across multiple metrics, demonstrating superior fidelity (data resemblance), utility (usefulness for downstream analysis), and privacy preservation.</li>
                    
                    <li>Identified a significant systematic miscalibration of type I error and statistical power when using generated data, highlighting a critical challenge for the validity of synthetic trials.</li>
                    
                    <li>Proposes a post-generation selection procedure that effectively improves the calibration of type I error and power, suggesting a pathway towards more reliable synthetic trial data, though acknowledging ongoing challenges.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The core methodology involves a Variational Autoencoder (VAE) architecture. This VAE is specifically engineered to jointly model and generate both discrete/continuous covariates (mixed-type) and time-to-event survival outcomes. It uses a unified latent variable framework to capture the complex dependencies between these data types, explicitly designed to handle censoring without assuming independence. The model's performance was benchmarked against GAN-based baselines using synthetic and real clinical trial datasets, assessed by fidelity, utility, privacy metrics, and statistical properties like type I error and power calibration.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The VAE model successfully generates high-fidelity and utilitarian synthetic clinical trial data, outperforming GAN baselines while preserving privacy. A critical discovery was the systematic miscalibration of type I error and power in studies utilizing synthetic data, which was subsequently improved by a proposed post-generation selection procedure, demonstrating the feasibility but also the existing validity challenges of generative survival modeling.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This technology has the potential to significantly impact clinical practice by enabling faster and more cost-effective clinical trials through the creation of synthetic control arms, reducing the number of patients required for trials, and facilitating data sharing for research. It could accelerate the development of new treatments for cancer and rare diseases, improve the statistical power of studies with limited patient populations, and enhance data privacy when sharing clinical trial information.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The primary limitation identified is the systematic miscalibration of type I error and statistical power when using synthetic data, which can affect the validity of conclusions drawn from trials using these methods. While a post-generation selection procedure offers improvement, it doesn't fully resolve the issue, indicating inherent challenges in perfectly replicating statistical properties of real data.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The paper explicitly highlights 'open challenges' for generative survival modeling, implying future research is needed to further refine the models to achieve more precise calibration of statistical properties (type I error, power). Continued development of robust post-generation selection or inherent model improvements will be crucial to ensure the full validity and trustworthiness of synthetic clinical trial data.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Rare Diseases</span>
                    
                    <span class="tag">Clinical Research</span>
                    
                    <span class="tag">Drug Development</span>
                    
                    <span class="tag">Biostatistics</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Generative AI</span>
                    
                    <span class="tag tag-keyword">Clinical Trials</span>
                    
                    <span class="tag tag-keyword">Synthetic Control Arms</span>
                    
                    <span class="tag tag-keyword">Survival Analysis</span>
                    
                    <span class="tag tag-keyword">Variational Autoencoder</span>
                    
                    <span class="tag tag-keyword">Censored Data</span>
                    
                    <span class="tag tag-keyword">Oncology</span>
                    
                    <span class="tag tag-keyword">Rare Diseases</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Clinical trials face mounting challenges: fragmented patient populations, slow enrollment, and unsustainable costs, particularly for late phase trials in oncology and rare diseases. While external control arms built from real-world data have been explored, a promising alternative is the generation of synthetic control arms using generative AI. A central challenge is the generation of time-to-event outcomes, which constitute primary endpoints in oncology and rare disease trials, but are difficult to model under censoring and small sample sizes. Existing generative approaches, largely GAN-based, are data-hungry, unstable, and rely on strong assumptions such as independent censoring. We introduce a variational autoencoder (VAE) that jointly generates mixed-type covariates and survival outcomes within a unified latent variable framework, without assuming independent censoring. Across synthetic and real trial datasets, we evaluate our model in two realistic scenarios: (i) data sharing under privacy constraints, where synthetic controls substitute for original data, and (ii) control-arm augmentation, where synthetic patients mitigate imbalances between treated and control groups. Our method outperforms GAN baselines on fidelity, utility, and privacy metrics, while revealing systematic miscalibration of type I error and power. We propose a post-generation selection procedure that improves calibration, highlighting both progress and open challenges for generative survival modeling.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>P. Chassat and V.T. Nguyen contributed equally to this work</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Journal Reference</h2>
                <p>Machine Learning for Health (ML4H) 2025</p>
            </section>
            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>